Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
Palliative Medicine
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Welsh, J.
Right arrow Articles by O'Neill, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Welsh, J.
Right arrow Articles by O'Neill, C.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Physicians' knowledge of transdermal fentanyl

John Welsh

Palliative Medicine, University of Glasgow, Palliative Medicine, Beatson Oncology Centre, Western Infirmary, Glasgow

Anne Reid

Department of Palliative Medicine, Beatson Oncology Centre, Western Infirmary, Glasgow

Julie Graham

Palliative Care, Wishaw General Hospital, Wishaw

Jorge Curto

Cancer Research UK, Beatson Labs, University of Glasgow, Glasgow

Karen MacLeod

Palliative Care, Beatson Oncology Centre, Western Infirmary, Glasgow

Claire O'Neill

Palliative Care, Beatson Oncology Centre, Western Infirmary, Glasgow

Background: Different opioids for use in the control of moderate to severe cancer pain have become widely available. More recently, sophisticated formulations such as transdermal patches have been developed. One example, transdermal fentanyl (TF), has characteristic pharmacokinetics and along with the other opioids, equivalency conversions are often made when changing from or to other opioids. Aim of study: To explore the knowledge of general practitioners (GPs), hospital consultants and oncologists about the pharmacology and use of TF in the management of moderate/severe cancer pain. Method: During 2001 and 2002 a questionnaire survey was carried out. A randomized selection of GPs, hospital consultants and oncologists (n-1167) from the UK and Ireland were sent a questionnaire and 576 (49%) were returned and evaluated. Results: The results show doctors who had previously prescribed TF are more confident and knowledgeable about the indications and pharmacology of TF than doctors who had never prescribed TF. Overall knowledge and confidence in using TF was poor.

Key Words: cancer pain • knowledge • pain control • pharmacology • physicians • transdermal fentanyl

Palliative Medicine, Vol. 19, No. 1, 9-16 (2005)
DOI: 10.1191/0269216305pm971oa
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Jpn J Clin OncolHome page
K. E. Clemens and E. Klaschik
Clinical Experience with Transdermal and Orally Administered Opioids in Palliative Care Patients--A Retrospective Study
Jpn. J. Clin. Oncol., May 22, 2007; (2007) hym017v1.
[Abstract] [Full Text] [PDF]